Based on first in class nanomotion technology platform, our rapid AST saves lives by finding the right antibiotic on time and reduces spreading of antibiotic resistance

The @Innovative Medicines for Tuberculosis (iM4TB) foundation, a Swiss non-profit fighting tuberculosis (TB), is pleased to announce a new partnership with @Resistell. The partners will harness Resistell’s proprietary Phenotech technology to further investigate iM4TB’s TB drug candidate, macozinone (PBTZ169).

Resistell, a leader in phenotypic nanomotion technology for measuring living cells, is proud to announce the launch of its next international, multisite clinical study, PHENOTECH-1.

Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, has taken another major step to achieving its vision by closing a first tranche of its series B financing round raising CHF 8.5M from new and existing investors.

Meet Resistell team at Bio Japan 2022 at Swisstech booth. Learn about World's fastest Antibiotic Susceptibility Test based on the first in class nanomotion technology platform!

To celebrate its 15th anniversary Venture Kick issued movie series about the impact VK alumni have on solving the most pressing global issues. See Resistell in an episode about antibiotic resistance. Thank you for featuring us!

Resistell, a TOP10 Swiss Start-up addressing the problem of speed in the diagnostics of antibiotic resistance, is pleased to announce they have initiated a research project to assess the applicability of Resistell’s antibiotic susceptibility test (AST) to a novel antibiotic. The project is funded by an independent grant from Pfizer AG.

Run in close collaboration with the microbiologists and infectious diseases specialists at the Lausanne University Hospital (CHUV) in Switzerland, the goal of the ongoing clinical study is to assess the sensitivity, specificity, accuracy and time to result of Resistell AST compared to the gold standard methods used at CHUV, namely Kirby-Bauer disc diffusion test and automated Vitek2 system® (bioMérieux). The study focuses on patients admitted to CHUV with bacteremia or sepsis due to Gram-negative bacteria.

Resistell is proud to be a part of SPEARHEAD project which launches to address the silent pandemic of antimicrobial resistance (AMR).

Resistell is proud to be featured in the "Startup Guide Basel Area".

Meet Resistell's team at the Swiss Symposium in Point-of-Care Diagnostics and see live presentation of our technology.